FDA rejection was attributed to a lack of substantial evidence of efficacy, including inconsistencies that undermined confidence in reproducibility across investigations. Reproxalap targets reactive ...

An FDA complete response letter for idebenone in LHON indicates unresolved NDA deficiencies and necessitates additional data before approval can be reconsidered. Priority review status and a February ...

Watch the incredible moment of a complete ball python hatch. Former MPP's Freedom Convoy-related case back on after stay of charges overturned Eddie Vedder's 15-year fight for EB cure may be on the ...

Neoadjuvant chemotherapy (NAC) is widely used in early-stage and locally advanced HER2-negative breast cancer, yet pathological complete response (pCR) is achieved in only a subset of patients.

Add Yahoo as a preferred source to see more of our stories on Google. Fact checking Trump's 2026 State of the Union address and Spanberger's response CBS News fact checked President Trump's 2026 State ...

Regulatory emphasis shifts from ORR and response duration to MRD negativity and CR as surrogate endpoints intended to shorten development timelines by capturing deeper molecular responses. MRD ...

The FDA issued complete response letters (CRLs) to two companies in recent days, resulting in vastly different reactions from the market. The U.S. regulator rejected Pharming’s bid to gain an ...

The Grammys are here again, and as music’s most prestigious night returns on Sunday, February 1, 2026, fans worldwide are already buzzing. From unforgettable moments like Lady Gaga’s tribute ...

Jan 30 (Reuters) - Shares of Corcept Therapeutics (CORT.O), opens new tab fell 16% on Friday after a corrected "complete response letter" from the U.S. Food and Drug Administration showed the agency ...

Triple-negative breast cancer (TNBC) is a highly aggressive malignancy with limited therapeutic options and elevated mortality rates. Chemo-immunotherapy according to the KEYNOTE-522 has established a ...

The MarketWatch News Department was not involved in the creation of this content. interim, subject to change, and based on data available as of a specified data cutoff date. No conclusions regarding ...